Thrombosis and cancer
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2014, Vol 31, Issue 3
Abstract
Cancer and hypercoagulability are two of the most common causes of morbidity and mortality worldwide. Their relationship was first reported in the mid 1800s, but it is only during the last 30 years that its mechanism has started to be elucidated. The risk of venous thromboembolism (VTE) among cancer patients is 4−6 times higher than among non-cancer patients and the likelihood of thrombosis is associated with parameters related to the patient and to the disease and its treatment. Malignancy affects all the parameters of the Virchow's triad: Blood-flow, coagulation procedure and endothelium. Cancer cells induce a hypercoagulant state by secreting procoagulant, antifibrinolytic and proaggregational factors and inflammatory mediators. Tissue factor production leads via coagulation-dependent and -independent pathways, to the creation of a vicious circle by which malignancy induces a thrombophilic state and thrombophilia, in turn, promotes tumor growth and metastasis. The spectrum of clinical and laboratory manifestations of cancer-related thrombosis is wide. In recent years efforts have been made to set up prognostic models to identify cancer patients at high risk for developing VTE, for whom the use οf thromboprophylaxis would be beneficial. Meanwhile, guidelines on thromboprophylaxis and the treatment of cancer-related thrombosis are being drawn up, and the use of anticoagulants as antineoplasmatic agents is under investigation.
Authors and Affiliations
A. ARGYROU, E. MERKOURI
Keywords
Related Articles
- EP ID EP121265
- DOI -
- Views 99
- Downloads 0
Spondylodiscitis
No abstract available
Middle East respiratory syndrome-coronavirus (MERS-CoV): A new threat?
The Middle East respiratory syndrome-coronavirus (MERS-CoV), which is based on the SARS virus and the extremely dangerous for public health, MERS virus, causes the "Acute Respiratory Syndrome of the Middle East", and it...
CONSORT 2010, explanation and elaboration: Updated guidelines for reporting parallel group randomised trials Greek translation − edition: S. Kokkali, C. Birtsou, A.B. Haidich Department of Hygiene and Epidemiology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
Overwhelming evidence shows that the quality of reporting of randomized controlled trials (RCTs) is not optimal. Without transparent reporting, readers can neither judge the reliability and validity of trial findings nor...
Treatment optimization of HBeAg-negative chronic viral hepatitis B with thymosin-α1
Chronic hepatitis B virus (HBV) infection is a widely prevalent and clinically significant condition with profound implications for health care costs worldwide. Interferon-α and direct antiviral nucleos(t)ide analogs suc...
Malaria: Two interesting cases of patients with fever <br /> <br />
Malaria is a serious and sometimes fatal disease caused by a parasite (Plasmodium spp) that commonly infects an infective female Anopheles mosquito which feeds on humans. Malaria typically is found in the warmer regions...